Arovella Therapeutics Limited (AU:ALA) has released an update.
Arovella Therapeutics Limited, listed on ASX as ALA, is making significant strides in advancing its iNKT cell therapy platform, with plans to commence a phase 1 clinical trial for ALA-101 targeting CD19-positive blood cancers. The company is financially robust, holding $13.2 million in cash and equivalents, which supports its ongoing research and development initiatives. Arovella has also formed a Clinical Advisory Board with leading experts to guide its progress in the cancer therapy landscape.
For further insights into AU:ALA stock, check out TipRanks’ Stock Analysis page.
